ATE466870T1 - Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems - Google Patents

Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems

Info

Publication number
ATE466870T1
ATE466870T1 AT03780353T AT03780353T ATE466870T1 AT E466870 T1 ATE466870 T1 AT E466870T1 AT 03780353 T AT03780353 T AT 03780353T AT 03780353 T AT03780353 T AT 03780353T AT E466870 T1 ATE466870 T1 AT E466870T1
Authority
AT
Austria
Prior art keywords
treatment
peptides
nervous system
central nervous
system diseases
Prior art date
Application number
AT03780353T
Other languages
English (en)
Inventor
Zhi Cheng Xiao
Original Assignee
Zhi Cheng Xiao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhi Cheng Xiao filed Critical Zhi Cheng Xiao
Application granted granted Critical
Publication of ATE466870T1 publication Critical patent/ATE466870T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03780353T 2002-12-06 2003-12-05 Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems ATE466870T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43162002P 2002-12-06 2002-12-06
PCT/GB2003/005323 WO2004052922A2 (en) 2002-12-06 2003-12-05 Peptides, antibodies thereto, and their use in the treatment of central nervous system damage

Publications (1)

Publication Number Publication Date
ATE466870T1 true ATE466870T1 (de) 2010-05-15

Family

ID=32507765

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03780353T ATE466870T1 (de) 2002-12-06 2003-12-05 Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems

Country Status (10)

Country Link
US (1) US7408028B2 (de)
EP (1) EP1567545B1 (de)
JP (1) JP2006526382A (de)
KR (1) KR20050092366A (de)
CN (1) CN1745094A (de)
AT (1) ATE466870T1 (de)
AU (1) AU2003288434B2 (de)
CA (1) CA2508847A1 (de)
DE (1) DE60332481D1 (de)
WO (1) WO2004052922A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006059959A1 (en) * 2004-12-01 2006-06-08 National University Of Singapore Nogo a protein fragments as neuronal network-interacting peptides
DE102004062420A1 (de) * 2004-12-20 2006-07-06 Rheinische Friedrich-Wilhelms-Universität Bonn Verfahren zur Isolierung neuraler Zellen mit Tenascin-R-Verbindungen
EP2168979A1 (de) * 2008-09-23 2010-03-31 Rheinische Friedrich-Wilhelms-Universität Bonn Verfahren zur Isolierung neuraler Zellen mit Tenascin-R-Verbindungen
JP2013502421A (ja) * 2009-08-21 2013-01-24 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー 癌治療のためのｃｄ４４融合タンパク質の使用方法
CN103122349B (zh) * 2011-10-21 2014-10-15 中国人民解放军第二军医大学 抑制MAG基因表达的siRNA及重组载体
CN103387603B (zh) * 2012-05-08 2015-07-15 复旦大学 一种rtn4b相关多肽及其制备与应用
TWI565712B (zh) * 2014-10-20 2017-01-11 福又達生物科技股份有限公司 增進神經元生長的胜肽及其應用
CN107312071B (zh) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗方法
EP4010012A1 (de) * 2019-08-08 2022-06-15 On. Target Molecules Biotech Inc. Fusionsproteine gegen sialosylierte glycosphingolipide und sialierte glykoproteine und deren verwendungen
WO2021231405A1 (en) * 2020-05-12 2021-11-18 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
CN113249420B (zh) * 2021-05-12 2022-08-26 四川原石科技有限公司 一种提高大鲵肽生物活性的方法、大鲵肽糖基化产物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735984B1 (fr) * 1995-06-30 1997-09-19 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
PT2275552E (pt) * 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Péptidos antigénicos de neisseria
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
YU53502A (sh) * 2000-01-12 2005-11-28 Yale University Blokada aksonalnog rasta posredstvom nogo receptora
GB0001825D0 (en) * 2000-01-26 2000-03-22 Regen Therapeutics Plc Peptides
US20020081590A1 (en) * 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
BR0108659A (pt) * 2000-02-25 2002-11-05 Oxford Glycosciences Métodos para tratamento ou prevenção ou profilaxia de câncer de mama, para detecção, diagnóstico e/ou avaliação ou prognóstico quanto ao câncer de mama, para monitoração e/ou estimativa de tratamento do câncer de mama, para identificação da presença ou ausência de células de câncer de mama metastáticas em um amostra biológica e para avaliação ou identificação de compostos, usos de uma ou mais bcmps, de uma composição, de um anticorpo, de ácido nucleico e de um agente que interaja com ou module a atividade de uma ou mais bcmps, vacina, composição, kit e anticorpo
AU2001251507A1 (en) * 2000-04-11 2001-10-23 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
CA2487247A1 (en) * 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
SG169231A1 (en) * 2002-12-06 2011-03-30 Singapore General Hospital Pte Ltd Nogo, caspr, f3 nb-3 useful in the treatment of injury and disease to the central nervous system

Also Published As

Publication number Publication date
CN1745094A (zh) 2006-03-08
JP2006526382A (ja) 2006-11-24
US20060205668A1 (en) 2006-09-14
KR20050092366A (ko) 2005-09-21
DE60332481D1 (de) 2010-06-17
CA2508847A1 (en) 2004-06-24
WO2004052922A3 (en) 2004-10-28
EP1567545A2 (de) 2005-08-31
US7408028B2 (en) 2008-08-05
EP1567545B1 (de) 2010-05-05
AU2003288434B2 (en) 2011-03-17
AU2003288434A1 (en) 2004-06-30
WO2004052922A2 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
DE60032486D1 (de) Prion protein peptide und deren verwendung
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
EA200501017A1 (ru) Астма и модуляторы аллергических воспалений
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
NO20061736L (no) Krystallform av epotilon B
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
DE69738868D1 (de) Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
ATE362928T1 (de) 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
WO2002069900A3 (en) Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
DK1294390T3 (da) Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DE60332481D1 (de) Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties